Proteomic and Genomic Profiling of Pancreatic Cancer

Dear Colleagues,

Pancreatic cancer is one of the deadliest forms of cancer, with a 5-year survival rate of 10%. The most common treatment for pancreatic cancer is surgery and chemotherapy; however, to date, both strategies have had limited success. To combat pancreatic cancer, in recent years, a significant amount of attention has been paid to immunotherapy and personalized medicine. PD1 therapy and presently available CART therapies are failing to treat pancreatic cancer, and there is a pressing need to collect more clinical biomarkers for the development of new therapeutic targets for personalized medicine. In the age of high-throughput techniques, genomics and proteomics in particular have had a significant impact on identifying mutations in oncogenes such as KRAS and other relevant new biomarkers for chemotherapy and immunotherapy. In addition, proteomic profiling of pancreatic cancer targeting secretomes will provide further insight into the tumor microenvironment, leading to a pivotal understanding of pancreatic cancer progression and immune response. Using the current understanding of immunotherapy, genomics and proteomics analysis of pancreatic cancer patient samples will lead to the discovery of new targets that will help in the development of novel therapeutics.

Dr. Aftab Alam
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.